sub:assertion {
<http://purl.obolibrary.org/obo/DOID_3491> bl:categorybl:Disease . sub:associationrdf:object <http://purl.obolibrary.org/obo/DOID_3491> ; rdf:predicatebl:treats ; rdf:subject <https://identifiers.org/drugbank:DB00052> ; ardf:Statement ; rdfs:label "norditropin is a recombinant human growth hormone indicated for pediatric 1 1 adult 1 2 norditropin somatropin rdna origin injection is indicated for the treatment of children with growth failure due to inadequate secretion of endogenous growth hormone gh norditropin somatropin rdna origin injection is indicated for the treatment of children with short stature associated with noonan syndrome norditropin somatropin rdna origin injection is indicated for the treatment of children with short stature associated with turner syndrome norditropin somatropin rdna origin injection is indicated for the treatment of children with short stature born small for gestational age sga with no catch up growth by age 2 4 years norditropin somatropin rdna origin injection is indicated for the replacement of endogenous gh in adults with growth hormone deficiency ghd who meet either of the following two criteria adult onset ao patients who have ghd either alone or associated with multiple hormone deficiencies hypopituitarism as a result of pituitary disease hypothalamic disease surgery radiation therapy or trauma or childhood onset co patients who were gh deficient during childhood as a result of congenital genetic acquired or idiopathic causes patients who were treated with somatropin for ghd in childhood and whose epiphyses are closed should be reevaluated before continuation of somatropin therapy at the reduced dose level recommended for ghd adults according to current standards confirmation of the diagnosis of adult ghd in both" ; bl:association_typebl:ChemicalToDiseaseOrPhenotypicFeatureAssociation ; bl:provided_by <https://w3id.org/um/NeuroDKG> ; bl:relationnkg:SymptomaticReliefIndication .
<https://identifiers.org/drugbank:DB00052> bl:categorybl:Drug . }